Drug intelligence / Profile preview

aqualief

Development stage: Unknown
Administration: Oral

Overview

Aqualief is an oral dietary supplement formulated as a mucoadhesive tablet, developed to help stabilize saliva flow and maintain neutral pH in the oral cavity, thereby improving the acid buffering capacity of saliva. It is intended for the management of **xerostomia** (dry mouth) of various etiologies. The tablet is specifically designed for patients with mild-to-moderate xerostomia (RTOG/EORTC grade 1-2). The mechanism of action is not fully elucidated, but the supplement acts locally in the oral cavity to alleviate symptoms of dry mouth by supporting saliva production and pH buffering[1].

Brand names: Aqualief

Beyond the preview

Go deeper on aqualief.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aqualief.

Explore the full profile